The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
about
Modulation of Autophagy by Sorafenib: Effects on Treatment ResponseTargeting Mcl-1 for the therapy of cancerHepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant HepatocytesA novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradationThe study of a novel sorafenib derivative HLC-080 as an antitumor agentUrsolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancerPhase II study of sorafenib in patients with relapsed or refractory lymphoma.A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.Targeted therapy in melanoma.Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibSorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed.A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasSorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesSystemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasA phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.Multiple mechanisms mediate resistance to sorafenib in urothelial cancerSorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destructionSynergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivoCholangiocarcinoma: molecular pathways and therapeutic opportunitiesThe multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cellsInhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisSorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.
P2860
Q26745320-A1D36835-9FAF-4426-A384-43F2A9630E89Q27011870-05669E29-4E04-4BBE-A6B5-B675EF0B4370Q27490901-A44D0379-A72C-4512-9178-17139E92FAF8Q27649579-579C2226-DA63-4011-9ADC-A040BE04BE5EQ28540521-02188DFF-8C93-42B7-9DB1-1FCBCBD24AD0Q28830045-B5759C5C-A5D8-4A12-BEA0-0B79D92AC2E7Q30317831-F62DB0D3-F7AC-4206-BEA9-3AFCD78BD603Q33266778-46E9147D-07C7-4FC0-AC9E-3B901BC74401Q33326515-24B2957C-606A-4FA0-B89C-C421310C85F6Q33401136-4063E9DD-19E7-4F23-A7FC-490836331D52Q33404952-7E5300AC-713B-46DA-9CFB-DE477967B6A1Q33509293-317E8340-6E22-4F4B-AABF-CB62A82C966FQ33514138-E8347C0A-FC04-4862-9C99-7F23C919807BQ33569854-A98FD055-8FDA-4F28-A1F3-68BE804C4FB2Q33573107-15DD3C5A-C0AB-45E6-86E2-E4751A9A012FQ33728138-A496C24F-8C2E-4E2F-9A9B-3E0E4B87A247Q33772438-89C3B1C7-BD26-4259-B474-C81F4DD064D9Q33780701-84E277D1-4628-47F3-B9B3-A04136920D94Q33780816-55008507-97AA-4F8C-B49A-516BB69A82FAQ33900952-742CF65C-DEED-42CC-B39C-964E0377EB63Q33917547-3EFCE35C-7319-47F7-BF75-69844B91B5D6Q33936548-F99898C0-C02B-412F-AA3B-7332E16AB6CDQ34063343-A8DEDEB4-BEC2-453A-8CB0-E3E5976CC07DQ34241371-3CE5620E-8192-4195-B65F-CA6F9F4BC845Q34329204-A707EED2-0B99-4326-BAF7-BCFF39A0B39BQ34408875-D6DA1C17-3BB0-45F8-9806-79642E00332DQ34451540-1D57D2A5-503C-4E73-9568-C267C53DC0C3Q34615116-4F6B4CB6-8971-4AA1-B91E-3383211161E1Q34685436-C39EBA62-71AC-4B47-BBD6-DC9A478152EDQ34689078-31AC9DEF-913D-4B4F-A516-BADFB68190A4Q34788849-6F05E5D6-BFBA-41CF-AEF3-0605AA2B9DD8Q34837850-D268527E-D6B7-49C7-844D-B85944E4D758Q34959174-BF0B5E6C-7559-4CFB-A731-9715A19FF6DAQ35038725-154D0C97-4772-4D5B-B43A-F3B5490CD7EBQ35080145-D0FE1D23-6896-4A7B-A428-1A84376A5694Q35125118-89490BF9-0AD4-4D57-8952-9B8DADA50BA8Q35147986-A7EC17E7-101D-4E55-ADF5-01F3221A8572Q35190181-BE5A017C-1265-459A-A5B5-7F0B83DBC7ADQ35570953-B818C93A-56A5-40EC-AB54-ABB80C75426BQ35740894-64843350-C546-49AA-8B3F-BEBCC8EE8800
P2860
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.
@en
type
label
The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.
@en
prefLabel
The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.
@en
P2093
P2860
P356
P1433
P1476
The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.
@en
P2093
Alex A Adjei
Christopher A Carter
Chunrong Yu
Laura M Bruzek
Scott H Kaufmann
Xue Wei Meng
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208841
P407
P577
2005-10-01T00:00:00Z
P5875
P6179
1053064977